ClinicalTrials.gg
CompletedNCT00356447Updated Oct 1, 2014

Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.

A Phase 3 interventional study of Estradiol/DRSP (Angeliq, BAY86-4891) and Placebo in Vasomotor Symptoms, sponsored by Bayer. Completed at 9 sites in China. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-10-01.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

The study evaluates in Chinese post-menopausal women the combination of drospirenone 2 mg and estradiol 1 mg for the treatment of climacteric symptoms, such as hot flushes (vasomotor symptoms) and uro-genital complaints.

Read the detailed description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.

02

Conditions studied

  • Vasomotor Symptoms
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese women with moderate to severe vasomotor symptoms

Exclusion criteria

Exclusion Criteria:

  • History of hormone dependent malignant disease
  • Known or suspected malignant or premalignant disease
  • Current or history of severe heart, liver, renal, psychiatric disease
  • Hyperlipemia
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
249 participants (actual)

Study arms

  • Active comparator
    Arm 1

    Drug: Estradiol/DRSP (Angeliq, BAY86-4891)

  • Placebo comparator
    Arm 2

    Drug: Placebo

Interventions

  • DrugEstradiol/DRSP (Angeliq, BAY86-4891)

    Drug pages: Estradiol · Drospirenone

    Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.

  • DrugPlacebo

    Same administration.

06

What researchers measure

Primary outcomes

  1. Frequency of hot flushes

    Time frame: From baseline to week 16

  2. Change in intensity of hot flushes

    Time frame: From baseline to week 16

Secondary outcomes

  1. Change in other climacteric symptoms

    Time frame: From baseline to week 16

  2. Vaginal Bleeding pattern

    Time frame: From baseline to week 16

  3. Global clinical impression

    Time frame: From baseline to week 16

07

Study locations

9 sites
  • Wuhan, Hubei 430032, China
  • Nanjing, Jiangsu 210029, China
  • Jinan, Shandong 250012, China
  • Beijing, 100020, China
  • Beijing, 100034, China
  • Beijing, 100083, China
  • Beijing, 100730, China
  • Chongqing, 400010, China
  • Shanghai, 200011, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2006
First posted
Jul 26, 2006
Start
May 2006
Primary completionActual
Oct 2007
CompletionActual
Oct 2007
Last update
Oct 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00356447
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 26, 2006
Start date
May 2006
Primary completion
Oct 2007
Completion
Oct 2007
Last update
Oct 1, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Drospirenone

Start the discussion